Evidence map›Paper›PMID 20556450›Full record

ReviewClinical rheumatology2010

Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.

Matthew B Carroll, Michael A Forgione

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Reactivation rates in patients using biological agents, with resolved HBV infection or isolated anti-HBc IgG positivity.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018
    Article
  13. Article
  14. Review
  15. Review
  16. Management of chronic hepatitis B in patients from special populations.Cold Spring Harbor perspectives in medicine · 2015
    Review
  17. Article
  18. Hepatitis B and Hepatitis C Reactivation in the Biologic Era.Journal of clinical and translational hepatology · 2014
    Review
  19. Review
  20. Management of patients with hepatitis B who require immunosuppressive therapy.Nature reviews. Gastroenterology & hepatology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Matthew B CarrollRheumatology, Keesler Medical Center, 301 Fisher Avenue, Keesler AFB, Biloxi, MS 39534, USA. matthew.carroll.1@us.af.mil
Michael A Forgione
Keesler Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a class, tumor necrosis factor (TNF)-alpha inhibitors have provided clinicians significant control over chronic inflammatory diseases. With their widespread use has come the emergence of new side effects such as the reactivation of latent infections. One such infection that may reactivate is the hepatitis B virus (HBV). It is currently unknown if HBV reactivation is a class effect or attributable to a particular TNF-alpha inhibitor. To answer this question, a comprehensive literature review to identify trends in related cases was performed. A systemic literature review was performed using the PubMed and Medline databases (1996 to January 2010) searching for the index term "Hepatitis B" combined with the terms "tumor necrosis factor," "TNF-alpha inhibitors," "etanercept," "adalimumab," "certolizumab," and "golimumab." All relevant articles in English were reviewed, and secondary references of interest were also retrieved. Thirty-five cases with hepatitis B surface antigen (HBsAg) positivity known prior to initiation of TNF-alpha inhibitors were identified. Infliximab was used in 17 cases, etanercept in 12 cases, and adalimumab in 6 cases. All six cases of clinically symptomatic hepatitis were associated with infliximab therapy. Infliximab was associated with the most cases of greater than 2-fold increase in alanine aminotransferase (six of nine cases) and greater than 1,000-fold increase in HBV DNA load (three of four). The two deaths reported occurred with infliximab therapy. Potential mechanisms of action for the reported observations include differences in molecular design, route of administration, and potency in clearing TNF-alpha. In patients with a positive HBsAg prior to starting a TNF-alpha inhibitor, infliximab has the most reported cases associated with HBV reactivation. While such reactivation may be due to a variety of reasons, clinicians prescribing TNF-alpha inhibitors to HBsAg-positive patients should consider prophylactic antiviral therapy and close monitoring for any clinical or serological evidence of hepatitis.

Indexed as

AdalimumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHepatitis B, ChronicHepatitis B Surface AntigensHepatitis B virusHumansInfliximabRheumatic DiseasesTumor Necrosis Factor-alphaAdalimumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHepatitis B Surface AntigensInfliximabTumor Necrosis Factor-alpha

Identifiers

PMID20556450
OpenAlexW2006249845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.